fda tirzepatide shortage resolved 2025 clarifies policies for compounders as national GLP-1 supply begins to stabilize Zepbound, Mounjaro shortages are resolved,

Kelly LP, Carvey PM, Keshavarzian A, Shannon KM, Shaikh M, Bakay RAE, et al

If approved, they create a personalized treatment plan

Semaglutide is a Glucagon-like Peptide-1 Agonist that stimulates the GLP-1 receptors in our body

Another trial found that people who took dulaglutide were 29% more likely to reduce their alcohol consumption than those on a placebo

However, coverage still depends on the specific TRICARE plan, provider network, and whether the treatment is considered medically necessary

As a GLP-1 receptor agonist, semaglutide can impact glucose metabolism and the immune response , potentially increasing the risk of yeast infections